Patents by Inventor Ehud Shahar

Ehud Shahar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS COMPRISING LTB AND PATHOGENIC ANTIGENS, AND USE THEREOF
    Publication number: 20230190923
    Abstract: The present invention is directed to compositions of immunogenic polypeptides including a heat labile toxin subunit B (LTB) polypeptide and a plurality of viral polypeptides. Further provided are compositions and methods of using same, such as for vaccinating a subject in need thereof.
    Type: Application
    Filed: February 25, 2021
    Publication date: June 22, 2023
    Applicant: MIGAL GALILEE RESEARCH INSTITUTE LTD.
    Inventors: Jacob PITCOVSKI, Ehud SHAHAR, Itai BLOCH, Itamar YADID, Ran BEN ADIVA, Chen KATZ, Nady GRUZDEV
  • Targeting of innate immune response to tumor site
    Patent number: 10188741
    Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: January 29, 2019
    Assignees: GAVISH-GALILEE BIO APPLICATIONS, LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Jacob Pitcovski, Ehud Shahar, Raphael Gorodetsky
  • TARGETING OF INNATE IMMUNE RESPONSE TO TUMOR SITE
    Publication number: 20160317675
    Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.
    Type: Application
    Filed: May 4, 2016
    Publication date: November 3, 2016
    Inventors: Jacob PITCOVSKI, Ehud SHAHAR, Raphael GORODETSKY
  • Targeting of innate immune response to tumor site
    Patent number: 9358307
    Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.
    Type: Grant
    Filed: January 25, 2009
    Date of Patent: June 7, 2016
    Assignees: GAVISH-GALILEE BIO APPLICATIONS LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Jacob Pitcovski, Ehud Shahar, Raphael Gorodetsky
  • TARGETING OF INNATE IMMUNE RESPONSE TO TUMOR SITE
    Publication number: 20110123629
    Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.
    Type: Application
    Filed: January 25, 2009
    Publication date: May 26, 2011
    Applicants: GAVISH-GALILEE BIO APPLIACTIONS LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPEMENT LTD.
    Inventors: Jacob Pitcovski, Ehud Shahar, Raphael Gorodetsky